^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LBA4 - Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced nonsquamous NSCLC in KEYNOTE-042
Published date:
12/12/2019
Excerpt:
Outcomes of pembrolizumab and of chemotherapy for pts with and without KRAS mutation and for KRAS G12C carriers are in the Table. Of note, CIs were wide given the modest frequency of KRAS mutation and low frequency of KRAS G12C...These findings also suggest that a pembrolizumab-containing regimen is a clinically relevant comparator for studies of KRAS -targeted therapy given as first-line treatment of NSCLC.
Trial ID:
Source:
Title:
Genetic Predictors of Benefit to Pembrolizumab
Excerpt:
...- Chemotherapy naïve NSCLC patients.For NSCLC patients with lung adenocarcinoma, tumors must be Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) wild-type; if a Kirsten Ras (KRAS) mutation is detected, EGFR and ALK testing is...
Trial ID:
Source:
Title:
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
Excerpt:
...Objective Response Rate (ORR)`Mutant KRAS Specific T cells...
Trial ID:
Less C2 evidence
Source:
Title:
66P - Outcome predictors for Pembrolizumab alone or with chemotherapy in advanced non-small cell lung cancer (NSCLC)
Published date:
03/23/2023
Excerpt:
Among patients harboring any KRAS mutations, we observed an advantage of Pembro-CT over Pembro in terms of PFS (p = 0.02), with a trend of benefit in OS….While no significant differences were found in OS, some patients, notably those harboring KRAS alterations, may benefit from the addition of chemotherapy.
Secondary therapy:
Chemotherapy
Source:
Title:
Pembrolizumab versus best supportive care survival outcomes in ECOG performance status 2 NSCLC patients
Published date:
03/23/2022
Excerpt:
...the median OS was 21 vs 2 months with Pembro and BSC (p<0.01) and was consistently better in Pembro patients among KRAS mutant patients...
Source:
Title:
KRAS mutations impact clinical outcome in metastatic non-small cell lung cancer
Published date:
02/14/2022
Excerpt:
KRAS mutations is a positive predictive factor for treatment with pembrolizumab and a negative predictive factor for platinum doublet chemotherapy as well as general OS in stage IV NSCLC.
DOI:
10.1101/2021.11.27.21266822v2
Source:
Title:
First-line pembrolizumab monotherapy for PD-L1-positive (TPS = 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort—ESCKEYP trial (GFPC 05-2018).
Published date:
05/19/2021
Excerpt:
Bispective, national and multicentric study including consecutively aNSCLC patients who initiated first-line pembrolizumab monotherapy...KRAS mutated: 27.7%, PDL1 TPS > 75%: 53.7%...With a median follow up of 25,8 [95%CI: 24,8-26,7] months, median rwPFS and median OS were 8,2 [95%CI: 6,9-9,5] and 22,6 [95%CI: 18,5-27,4] months, respectively; 6, 12, 18-months survival rates were 76,8%, 64,8% and 54,3%....
DOI:
10.1200/JCO.2021.39.15_suppl.9091
Source:
Title:
Complex markers of survival from pembrolizumab: the potential predictive role of tumor mutational burden (TMB) and KRAS
Published date:
11/09/2020
Excerpt:
We identified a cohort of metastatic EGFR/ALK wild type NSCLC patients...KRAS mutant status was independently significant for OS benefit from pembrolizumab + chemotherapy [HR=0.01; CI=0.01–0.79; p=0.04] but not for pembrolizumab monotherapy or chemotherapy alone.
Secondary therapy:
Chemotherapy
Source:
Title:
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Excerpt:
To further confirm these observations from a public database, we prospectively collected 20 NSCLC (15 ADC) patients who were treated with pembrolizumab (n = 11) or nivolumab (n = 9) from August 2015 to August 2016 in our center (GLCI)….Patients with TP53 and/or KRAS mutation showed prolonged PFS than both genes negative patients treated with PD-1 inhibitors.
DOI:
10.1158/1078-0432.CCR-16-2554
Trial ID:
